Boston Trust Walden Corp Reduces Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Boston Trust Walden Corp reduced its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 4.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,513,975 shares of the biotechnology company’s stock after selling 69,924 shares during the period. Boston Trust Walden Corp owned approximately 1.45% of Corcept Therapeutics worth $70,067,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Park Place Capital Corp purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at about $32,000. Atwood & Palmer Inc. purchased a new stake in Corcept Therapeutics in the second quarter valued at approximately $35,000. Kathleen S. Wright Associates Inc. acquired a new position in Corcept Therapeutics in the 3rd quarter worth approximately $36,000. FinTrust Capital Advisors LLC raised its position in Corcept Therapeutics by 318.7% during the 1st quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,348 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Corcept Therapeutics by 125.4% during the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,962 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 10,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total value of $353,000.00. Following the completion of the transaction, the insider now directly owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total transaction of $509,080.00. Following the completion of the sale, the insider now owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Guyer sold 10,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the completion of the sale, the insider now owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,251 shares of company stock valued at $1,365,292 over the last quarter. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Price Performance

NASDAQ CORT traded up $0.04 during trading hours on Friday, reaching $47.28. The company’s stock had a trading volume of 933,325 shares, compared to its average volume of 1,183,725. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of 44.60 and a beta of 0.46. The company’s 50-day moving average is $41.05 and its two-hundred day moving average is $33.73. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $50.07.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.09. The business had revenue of $163.80 million for the quarter, compared to the consensus estimate of $155.14 million. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The company’s revenue was up 39.1% compared to the same quarter last year. During the same period last year, the firm posted $0.25 earnings per share. Equities analysts forecast that Corcept Therapeutics Incorporated will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CORT shares. Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, September 18th. HC Wainwright lifted their price objective on Corcept Therapeutics from $45.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, July 30th. Finally, Truist Financial upped their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.